BioWave is a neuromodulation pain therapy company whose major goal is to help physicians, physical therapists and athletic trainers manage their patients' or athletes pain and reduce or eliminate the use of opiates, NSAIDs and their associated side effects. Biowave devices deliver a therapeutic electrical signal into deep tissue in the body blocking the transmission of pain.
Missing: BioWave's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioWave's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioWave
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioWave is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
BioWave has filed 1 patent.
Electrotherapy, Neurotechnology, Medical treatments, Medical devices, Neurophysiology
Electrotherapy, Neurotechnology, Medical treatments, Medical devices, Neurophysiology
Latest BioWave News
Jun 2, 2022
News provided by Share this article CT Senator, Chris Murphy Recognized BioWave for Continued Innovation of BioWave's Patented Pain Blocking Technology. Senator Chris Murphy (D-Conn.) announced that BioWave, based in Norwalk, CT, has been named April's "Innovator of the Month." BioWave is a patented smarter pain blocking technology that provides immediate, deep, long-lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain signals from reaching the brain relieving chronic, acute or post-operative pain. BioWave's technology has helped professional and college athletes, veterans and others suffering from chronic pain, get closer to a pain-free life and return to daily activities without the use of opioids. BioWave recently introduced a new patent pending product family called BioWraps® which are wearable compression electrode garments that are paired with BioWave's pain blocking neurostimulators. BioWraps use a proprietary silver fabric technology that allow for treating up to 5X the volume of tissue as compared to conventional electrodes while simultaneously providing compression and support. CT Senator, Chris Murphy Recognized BioWave for Continued Innovation of BioWave's Patented Pain Blocking Technology "Imagine being able to treat and reduce pain across the entire lower back. We've also designed BioWraps for numerous other locations on the body. Our Foot/Ankle BioWrap is designed to treat pain throughout the entire foot and ankle, so we are very excited about the opportunity to help patients that suffer from painful diabetic neuropathy," said Bradford Siff, Founder & President. "We help manage severe pain and reduce opioid consumption for over 10,000 veterans per year in over 190 VA Hospitals and CBOCs (Community Based Outpatient Clinics) around the country, and we believe BioWraps are a superior technology for providing the highest level of relief for Veterans," said Robert Adler, Chairman. "The team at BioWave is transforming pain care management for the millions of Americans who suffer from chronic pain that interferes with their daily lives. Their technology provides a safe, effective alternative to opioids that helps ease persistent pain, and I'm proud to recognize their innovative work in Connecticut," said Murphy. "We are honored to be recognized by Senator Murphy. One of the keys to innovation is having access to capital as well as to high level resources that can facilitate the ideation, design and development process. Being located in Connecticut helps provide easier access to capital and to these key individuals and core outside services. So for example, we were delighted to have the State of Connecticut's venture capital arm, Connecticut Innovations, participate in our most recent round of preferred equity financing several years ago," said Bradford Siff. Murphy believes entrepreneurship and innovation are the building blocks for a strong economy. In the U.S. Senate, he has introduced two bipartisan pieces of legislation to incentivize angel investors to put more money into startup companies—the Angel Tax Credit Act and the Helping Angels Lead Our Startups (HALOS) Act. Startup companies create an average of 2 million jobs each year. About BioWave Corp. BioWave is committed to delivering immediate, deep, and long-lasting relief to severe pain by offering innovative solutions to treat pain using the company's patented, high-frequency neurostimulation technology . Products include BioWavePRO and BioWavePENS, for use in a physician's office, BioWaveHOME RX, a home prescription portable version, BioWave GO RX, a portable unit, BioWaveGO an over-the-counter device, and BioWraps, wearable electrode compression garments. BioWave technology and solutions are widely and used by many VA hospitals, active military bases, pain, and ortho clinics, along with professional and collegiate sports teams. BioWave devices are FDA-cleared, and clinically proven to deliver safe and effective treatment of pain without the need for prescription drugs. BioWave is available under Federal Supply Schedule contract number V797D-70205. More information about the company's products and solutions can be found at BioWave.com . Contacts
BioWave Web Traffic
BioWave Frequently Asked Questions (FAQ)
When was BioWave founded?
BioWave was founded in 1997.
Where is BioWave's headquarters?
BioWave's headquarters is located at 8 Knight Street, Norwalk.
What is BioWave's latest funding round?
BioWave's latest funding round is Corporate Minority.
How much did BioWave raise?
BioWave raised a total of $3.54M.
Who are the investors of BioWave?
Investors of BioWave include Platform-14, Paycheck Protection Program, JHK Investments, Loeb Partners and Circle Peak Capital.
Who are BioWave's competitors?
Competitors of BioWave include Relievant Medsystems, eNeura Therapeutics, Light Sciences Oncology, SteadyMed Therapeutics, Paragon Medical and 12 more.
Compare BioWave to Competitors
AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.
Salutaris Medical Devices (SalutarisMD) is a clinical-stage medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). SalutarisMD is developing a minimally invasive procedure that can be performed in an outpatient or physician office setting in approximately 15 minutes.
Facet Solutions has developed a total replacement for the facet joint to treat back pain from hypertrophy.
Relievant provides the underserved population with a low-risk therapy that can eliminate back pain while preserving other therapeutic options. The Company's Intracept System is a minimally invasive procedure that uses radiofrequency energy delivered through a small access tube into the vertebral body to ablate the Basivertebral nerve. The nerve, thought to significantly contribute to chronic low back pain, can no longer generate pain signals following ablation. The company was founded in 2004 and is based in Minneapolis, Minnesota.
eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.
Sunlight Medical is a medical technology company engaged in the development, manufacture, and marketing of medical devices for physician's offices and hospitals. The company aims to become a provider of technology-intensive solutions that enable primary care practitioners to deliver high quality care at an cost.Sunlight comprises research and development headquarters in Israel and regional subsidiaries in Europe, Asia, and the United States. Sunlight has established strong sales and distribution channels in the relevant markets within these regions and sold thousands of its units worldwide. Since it was founded in 1995, Sunlight has become a player in the global osteoporosis diagnosis market.Sunlight devices, with radiation-free, user-friendly technologies to provide services that fit physicians' needs, are marketed both to small practices and to hospitals. The products are very reliable, highly accurate, moderately priced, and offer a profitable business model.Sunlight's osteoporosis management products include Sunlight Omnisense' 7000S, a noninvasive quantitative-ultrasound device developed for quick, user-friendly assessment of fracture risk and osteoporosis management, and Sunlight Omnisense' 8000S, the world's only multi-site portable bone assessment device.Products for the pediatric market include Sunlight BonAge, a quantitative ultrasound device for accurate bone age evaluation to be released in 2003. Current pediatric products are Sunlight Omnisense' 7000P for monitoring bone development in children and adolescents and Sunlight PREMIER for bone assessment in premature babies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.